AUTHOR=Mahajan Abhimanyu , Chirra Martina , Dwivedi Alok K. , Sturchio Andrea , Keeling Elizabeth G. , Marsili Luca , Espay Alberto J. TITLE=Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study JOURNAL=Frontiers in Neurology VOLUME=Volume 11 - 2020 YEAR=2020 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2020.00406 DOI=10.3389/fneur.2020.00406 ISSN=1664-2295 ABSTRACT=Objective: To evaluate the extent to which cancer, a biological opposite to neurodegenerative disorders, may affect onset and progression of Parkinson’s disease (PD). Methods: A nested case-control design in consecutive PD patients with (cases) versus without cancer (controls) was used to compare time to clinical diagnosis and time to Hoehn & Yahr (H&Y) staging score≥3 as a measure of progression. Further, we compared PD onset and progression between cases with cancer diagnosis before (cancer before PD group) and after PD onset (cancer after PD group). Independent variables were age at PD onset, motor subscale of Movement Disorders Society-Unified Parkinson’s Disease Rating Scale, sex, cognitive impairment, falls, depression, anxiety, dementia and autonomic symptoms. Time to H&Y≥3 was determined using Cox proportional hazards, with adjusted results summarized as hazards ratio (HR). Group differences were evaluated using unpaired t-test or Fisher’s exact test. Results: The clinical PD onset was later in cases versus controls (median 67.2 vs 59.8 years; p < 0.001) but the adjusted time to H&Y≥3 was similar between groups (HR=0.67; p=0.13). Skin cancers constituted 75% of all cancers in cases. Amongst skin cancers, compared to controls, cases had an older age at PD onset (67.8 vs 59.8 years; p < 0.001). There was no difference in risk of progression in PD patients with skin cancer compared to controls (HR=0.54, p=0.09). Conclusions: Cancer, in particular of skin, may delay onset but not progression of PD. Future prospective observational studies are warranted to elucidate the complex interactions between these biologically divergent disorders.